WASHINGTON, June 3, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, will present Phase 3 rifaximin study data at Digestive Disease Week (DDW) in Washington, D.C., from June 2-5, 2018.
"We are proud to showcase this data at DDW to leading gastroenterologists and researchers to continue to reiterate the benefits of rifaximin for patients with irritable bowel syndrome with diarrhea (IBS-D)," said Mark McKenna, senior vice president and general manager, Salix Pharmaceuticals. "Our customers, including both patients and healthcare professionals, are our top priority and we will continue researching to ensure their needs are met."
The complete schedule of oral and poster presentations that will be presented on rifaximin data at DDW on June 3 includes:
"The data presented at DDW continues to support the efficacy of rifaximin for patients with IBS-D," said Mark Pimentel, M.D., professor of Medicine and executive director of the Medically Associated Science and Technology Program, at Cedars-Sinai, in Los Angeles, CA. "I'm encouraged by these results that help us understand the extent to which Clostridium difficile (C. Diff) may occur with Xifaxan."
About XIFAXAN
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch/ or call 1-800-FDA-1088.
For product information, adverse event reports, and product complaint reports, please contact:
Salix Product Information Call Center
Phone: 1-800-321-4576
Fax: 1-510-595-8183
Email: salixmc@dlss.com
Please click here for full Prescribing Information.
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world and is committed to the prevention and treatment of gastrointestinal diseases. For almost 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix, a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., is headquartered in Bridgewater, New Jersey.
The Xifaxan 550 mg product and the Xifaxan trademark are licensed by Alfasigma S.p.A.to Salix Pharmaceuticals or its affiliates. SAL.0070.USA.18
SOURCE Salix Pharmaceuticals, Ltd.